Hospitals across the country celebrate improvements to patient safety
TORONTO, Oct. 30, 2019 /CNW/ - During this year's Canadian Patient Safety Week, hospitals from across the country are celebrating important improvements to patient safety.
"Three years ago, hospitals from seven provinces joined forces to raise awareness among pharmaceutical suppliers of what our hospitals needed to help safeguard our patients," said Spencer Tuttle, Director, Lower Mainland Pharmacy Services. "By working with industry, we have made important advancements in barcoding, advance notification of product changes and new products that can help mitigate medication errors and make the supply chain more efficient."
The pan-Canadian effort was coordinated through HealthPRO, the national group purchasing organization that over 1,300 healthcare facilities leverage to maximize their buying power on healthcare contracts.
"It was our honour to amplify the needs of member hospitals through the Transforming Together campaign," says Christine Donaldson, Vice President, Pharmacy at HealthPRO. "Through the dedication of so many pharmacists and many others across the country, we have collectively moved the needle forward to improve the safety of patients."
Successes achieved to date include:
20% increase in barcodes on a medication's unit-of-use; Barcodes on an injectable medication's unit-of-use (vial, ampoule, pre-mixed bag) can help safeguard against errors at the most vulnerable stage of the medication use process – during administration to a patient. In fact, evidence shows that scan verification of the medication at the bedside can help reduce patient error in hospitals by up to 41%1.
Prior to the launch of this campaign, many of the commercial products delivered to hospitals did have barcodes on the external packaging or box, but not on the unit-of-use, the format that would ultimately be administered to a patient. The absence of this feature critical for verification, can introduce risk and the need for hospital pharmacy staff to assume the task of creating and applying barcodes, often a manual and time-consuming undertaking.
The campaign propelled a 20% increase in barcodes on the unit-of-use by the supplier, minimizing the risk of medication errors.
Implemented a national protocol for the advance notification of product changes;
Hospitals are increasingly automated facilities, featuring a wide array of technology from robotics, automated packaging and labelling machines, to optical verifiers and compounding pumps.
This automation is designed to enhance resource efficiencies and contribute to medication safety – however when changes are made to pharmaceutical products that interface with these technologies without sufficient notice, unexpected and sometimes serious consequences can occur, including medication errors.
To mitigate such consequences, many pharmaceutical suppliers now provide at least 60 days' advance notice of product changes to HealthPRO, who in turn communicates them to hospitals across the country to adjust their automation protocols. This advance notification can help mitigate a cost to the system which simply cannot be measured.
Helped introduce 36 new commercially available medications that meet patient safety objectives Through this collective effort, hospitals helped accelerate the development of fit-for-purpose medications to facilitate appropriate and accurate dosing. These are new products, such as lower strength medications in the actual dose required by patients, that suppliers have produced based on the specific needs of hospitals across the country which enhance patient safety and bring efficiency to the internal hospital supply chain.
HealthPRO is committed to supporting hospitals in delivering on the next level of success for their patients. This fall, HealthPRO hosted another event which brought over 200 representatives from pharmaceutical companies and hospital leadership together. This time, the challenge was — how do we strengthen the health of our Canadian drug supply chain and minimize drug shortages?
Drug shortages are a complex, global problem, but ideas generated during this most recent session show great promise. In fact, 99% of attendees agreed that ideas generated during this event have the potential to improve the drug supply chain.
About HealthPRO
HealthPRO is Canada's group contracting provider for healthcare.We put decades of knowledge and the purchasing volumes of more than 1,300-member healthcare facilities across Canada to work. Our members count on us to reduce the cost of high-quality products and services they use, improve patient safety, help maintain assurance of supply and pursue new ideas and innovations. The outcome is unprecedented buying power and market influence for Canadian healthcare facilities. For more information, please visit www.healthprocanada.com.
About Canadian Patient Safety Week
Canadian Patient Safety Week is a national, annual campaign that the Canadian Patient Safety Institute started in 2005 to inspire extraordinary improvement in patient safety and quality. As the momentum for promoting best practices in patient safety has grown, so has the participation in Canadian Patient Safety Week. Canadian Patient Safety Week is relevant to anyone who engages with our healthcare system: providers, patients, and citizens. Working together, thousands help spread the message to Conquer Silence. For more information, please visit www.patientsafetyinstitute.ca
_____________________________
1 Poon EG et al. Effect of Bar Code Technology on the Safety of Medication Administration. N Eng J Med 2010; 362:1698-1707)
SOURCE HealthPRO Procurement Services Inc.
Spectrum Therapeutics and Tree of Knowledge Announce Partnership to Educate and Support Healthcare Professionals
SMITHS FALLS, ON, Oct. 30, 2019 /CNW/ - Spectrum Therapeutics, the medical division of Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NYSE: CGC) is pleased to announce that it has partnered with Tree of Knowledge International Corp. ("Tree of Knowledge") (CSE: TOKI) (OTC: TOKIF) to provide education and support for patients and their healthcare professionals working within the Tree of Knowledge healthcare network across Canada.
As part of the two year agreement, Spectrum Therapeutics will collaborate with Tree of Knowledge's partner clinic, Jack Nathan Health, to launch several e-learning modules on its online education platform for healthcare professionals practicing in Jack Nathan clinics. In addition, Spectrum Therapeutics will host live webinars presented by leading Canadian experts on medical cannabis including: Dr. Kevin Rod, director of Toronto Poly Clinic multidisciplinary pain management clinics and Tree of Knowledge's Chief Medical Officer; Canopy Growth's Chief Medical Officer, Dr. Mark Ware and its Director of Global Medical Services, Dr. Danial Schecter. Topics that will be covered include an overview of medical cannabis and best practices for prescribing and dosing as well as chronic pain management and opioid reduction.
Through its partnership with Jack Nathan Health, Tree of Knowledge will offer Chronic Pain Management and Medical Cannabis education programs in Jack Nathan clinics, which are located in 74 Walmart stores across six Canadian provinces and, on a combined basis, have more than 1.5 million patient visits annually. Jack Nathan Health also has six clinic locations in Mexico which are ideally positioned to support the opening of the Mexican medical cannabis market while leveraging Spectrum Therapeutics' global expertise in patient and physician education.
"Continuing to invest in training and education programs remains a priority for us as a gap in knowledge still exists for many healthcare professionals when it comes to medical cannabis," comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "By partnering with Tree of Knowledge we're able to deliver these initiatives at scale which will provide more patients with access to knowledge on the potential of cannabis to address their needs with the guidance of a doctor."
Spectrum Therapeutics and Tree of Knowledge will also work together on patient education including an animated video series and a customized patient dosing diary. Education programs will focus on topics like multidisciplinary pain management and opioid reduction programs.
"The need for patient and provider cannabis education has grown substantially since legalization one year ago," said Michael Caridi, Chairman of Tree of Knowledge. "This strategic partnership with a global leader like Spectrum Therapeutics places focus squarely on educating patients in a medical setting. This partnership will launch targeted educational campaigns for patients in addition to providing training and support to their health care providers."
About Canopy Growth Corporation Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.
Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.
Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 10.5 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
About Spectrum Therapeutics Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, furthering the public's understanding of medical cannabis and its various applications, and cutting edge, commercializable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded spectrum to categorize medical cannabis according to THC and CBD levels.
Spectrum Therapeutics' offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.
About Tree of Knowledge With its head office in Toronto, and operations in North York, Ontario and Spokane, Washington, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, including controlled applications of medical cannabis in Canada, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at its manufacturing facility in Spokane, which provides formulations for the Company's products and for third parties equivalent to GMP standards, and (3) Distribution and sale of hemp-based cannabidiol ("CBD") products in the United States, Canada, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience. The Company has developed and implemented MCERP (Medical Cannabis Education, Research and Best Practice Platform) and MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development. TOKI's CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States. TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes. https://www.tokicorp.com/
About Jack Nathan Health®Jack Nathan Health® is a privately owned and operated Canadian company—and a proud partner of Walmart Canada—dedicated to improving access to healthcare by partnering with highly-qualified medical professionals and delivering consistent, easy-access, patient-centric quality care in state-of-the-art medical and dental clinics conveniently located inside Walmart Supercenters, with 70-plus locations across Canada. Clinics are independently owned and operated under license by Jack Nathan Medical Inc., and not affiliated with Walmart. Jack Nathan Health® is a registered trade-mark of Jack Nathan Medical Inc. All representations contained herein are made solely by Jack Nathan Health® or its licensed owner operators, and not independently verified by Walmart. All Walmart trademarks are the property of Wal-Mart Stores, Inc. and are used under license. For more information, virtual clinic tours, and social media links, visit www.jacknathanhealth.com.
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include "will host live webinars presented by leading Canadian experts on medical cannabis" and "will also work together on patient education including an animated video series and a customized patient dosing diary". Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the development and delivery of educational content, and such risks contained in the Company's annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Spectrum Therapeutics
How Sun Life is transforming digital healthcare one click at a time
Lumino Health surpasses 10 million provider ratings
TORONTO, Oct. 30, 2019 /CNW/ - Today, Lumino Health is celebrating one year of helping Canadians find their healthcare match online. To date, Sun Life Clients have submitted over 10 million ratings for the healthcare providers on LuminoHealth.ca – Canada's premier digital network of health resources.
"Lumino Health makes it possible to deliver on Sun Life's Purpose of helping our Clients achieve lifetime financial security and live healthier lives," said Chris Denys, Senior Vice-President, Possibilities, Sun Life. "Sun Life processes millions of claims every year from healthcare providers across Canada which means we're able to hear from real people based on their own experience or that of their family members."
As part of Sun Life's focus on Sustainability, the company is committed to providing all Canadians with the tools and education needed to live healthier lives. Through investments in community health, thought leadership, and access to health and disability insurance, Sun Life is focused on improving health and wellness in society.
"Lumino Health gives Canadians instant access to information about healthcare products and providers," said Denys. "With just one easy click, Canadians can search for healthcare resources and providers ranked by priority criteria such as cost, convenience, quality ratings, location, languages spoken or speciality. It also gives Canadians the ability to connect to these providers instantly – to consult, book an appointment, or arrange a delivery."
Ratings on more than 150,000 health providers including dentists, massage therapists, chiropractors, physiotherapists, psychologists, vision care providers, naturopaths, acupuncturists and more from coast to coast;
Helpful information on providers such as hours of operation, cost comparisons, languages spoken and the ability to request an appointment online;
The latest apps, products and solutions from health innovators supported by reviews from a community of users; and
Insights from health industry experts on how to live a healthier life.
Connect with Lumino Health and Sun Life @LuminoHealth @SunLifeCA
About Sun Life Sun Life is a leading international financial services organization providing insurance, wealth and asset management solutions to individual and corporate Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of June 30, 2019, Sun Life had total assets under management of $1,025 billion. For more information please visit www.sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Note to editors: All figures in Canadian dollars
Media Relations Contact: Kathleen Savage Manager, Corporate Communications Corporate Communications T. 416-979-6396 kathleen.savage@sunlife.com
SOURCE Sun Life Financial Inc.
Aurora Cannabis Launches National Safety Campaign on Edibles
'Ready for Edibles' addresses safe storage, responsible consumption, and differences in cannabis products
EDMONTON, Oct. 30, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today announced the launch of Ready for Edibles, a national bilingual campaign dedicated to educating new and experienced cannabis consumers on responsible consumption and safe storage of edibles products before they become available for sale in December.
In the visual style of Not Safe For Work (NSFW)¸the campaign creative will depict blurred images of cookies, gummies and other edibles products stamped with the wording: ADULTS ONLY, stating "Edibles are coming and they're not for kids. Ask a budtender or learn more at www.readyforedibles.com"
The campaign can be seen at cannabis retail outlets across Canada and will be complemented online with digital and video assets as well as radio, television and out-of-home opportunities.
"The roll-out of Aurora's next generation of high-quality cannabis products is very exciting and we are proud to be able to offer new forms like vapes, concentrates and edibles," said Terry Booth, CEO of Aurora. "We want to make sure consumers have the information they need to understand the differences in these products, how to consume them responsibly, and most importantly, that they should be kept away from children and pets."
Educational content will also focus on identifying signs of over-consumption, understanding the differences in onset times and effects, cautions around mixing with alcohol and driving while intoxicated. All of Aurora's NextGen cannabis products, including cookies, gummies, chocolates and mints, will include the certified, lab-tested concentration of THC and CBD.
Check out the campaign creative attached to this release.
Before you get started with edibles, prepare yourself by learning how to consume safely. Visit www.readyforedibles.com to learn more.
About Aurora
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora's facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Aurora's first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.
In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and is a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor website, investor.auroramj.com
Terry Booth, CEO Aurora Cannabis Inc.
SOURCE Aurora Cannabis Inc.
Janssen Announces Health Canada Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
This DARZALEX®combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible
TORONTO, Oct. 30, 2019 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved under Priority Review DARZALEX® (daratumumab), in combination with lenalidomide and dexamethasone (Rd), for newly diagnosed patients with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The approval is based on results from the Phase 3 MAIA clinical study published in the New England Journal of Medicine, which showed the DARZALEX®-Rd combination reduced the risk of disease progression or death by 44 per cent compared to treatment with Rd alone.1
Multiple myeloma is an incurable blood cancer associated with the abnormal behaviour and uncontrolled growth of plasma cells in the bone marrow.2 Every day, approximately nine Canadians are diagnosed with multiple myeloma,3 but the cause or causes remain unknown4 and it can be difficult to diagnose.5 Advancements in research have led to the discovery of new therapies and combination therapies, providing hope for patients.6 Work is ongoing with both public and private insurers to determine how DARZALEX® can be made accessible for newly diagnosed, transplant ineligible patients.
"In multiple myeloma it is essential to administer the most effective therapy early, ideally as first line, to prevent disease relapse and the emergence of resistant clones. The use of daratumumab in combination with lenalidomide and dexamethasone resulted in unprecedented depth and durability of response with eradication of all detectable disease in a quarter of patients in the study," says Dr. Nizar Bahlis, Associate Professor, Cumming School of Medicine (CSM), University of Calgary and member of the CSM's Arnie Charbonneau Cancer Institute. "Based on the data, it is expected that this regimen should become the new standard to treat newly diagnosed transplant ineligible patients with multiple myeloma."
This marks the fourth approval for DARZALEX®. In June 2016, Health Canada approved DARZALEX® for those with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD (meaning they didn't respond to or relapsed while on those treatments).7 In April 2017, the medication was approved for use earlier in the disease - for patients who have received at least one prior therapy. For these patients, DARZALEX® is used in combination with either lenalidomide and dexamethasone, or with bortezomib and dexamethasone.8 In November 2018, the medication was approved in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of newly diagnosed patients with multiple myeloma who are transplant ineligible.
The Health Canada approval of DARZALEX®-Rd is supported by data from the randomized, Phase 3 MAIA study. Results showed DARZALEX® in combination with Rd reduced the risk of disease progression or death by 44 per cent in patients with newly diagnosed multiple myeloma who are transplant ineligible compared to treatment with Rd alone (Hazard Ratio [HR] = 0.56; 95 per cent confidence interval [CI]: 0.43-0.73; p<0.0001).9 At a median follow-up of 28 months, the median progression-free survival (PFS) for DARZALEX®-Rd has not yet been reached, compared to 31.9 months for patients who received Rd alone.10, 11 The addition of DARZALEX® to Rd resulted in deeper responses compared to Rd alone, including increased rates of complete response (CR) or better (48 per cent vs. 25 per cent), very good partial response or better (79 per cent vs. 53 per cent) and overall response (93 per cent vs. 81 per cent).12 Twenty-four per cent of patients in the DARZALEX®-Rd group achieved CR or better and minimal residual disease (MRD) negativity status (10-5) compared to 7 per cent in the Rd group, representing a >3-fold higher rate.13
In the study, the most frequently reported Treatment Emergent Adverse Events (TEAEs) (≥20 per cent) in the DARZALEX®-Rd arm were: infusion-related reactions, diarrhea, neutropenia, constipation, fatigue, peripheral edema, anemia, back pain, asthenia, nausea, insomnia, muscle spasms, bronchitis, dyspnea, weight decreased, cough, peripheral sensory neuropathy, pyrexia, upper respiratory tract infection, pneumonia, decreased appetite, and hypokalemia.14 Serious TEAEs with a 2 per cent higher incidence in the DARZALEX®-Rd arm compared to the Rd arm were pneumonia (15 per cent vs 8 per cent) and bronchitis (4 per cent vs 2 per cent).15 Treatment-emergent Grade 3/4 hematology laboratory abnormalities (≥20 per cent) were neutropenia (56 per cent), lymphopenia (52 per cent) and leukopenia (35 per cent).16 The safety profile of DARZALEX® was generally consistent with that of previous studies.17
About Multiple Myeloma Multiple myeloma is the most common plasma cell cancer18 and is characterized by an excess proliferation of plasma cells.19 In Canada, there were an estimated 3,317 new cases in 2019 and an estimated 1,563 deaths associated with the disease.20 While some patients with multiple myeloma have no symptoms in the early stages, patients are diagnosed due to symptoms that can include bone disease or pain, anemia, calcium elevation, and kidney problems.21
About the MAIA Trial The randomized, open-label, multicenter Phase 3 study included 737 newly diagnosed patients with multiple myeloma ineligible for high-dose chemotherapy and ASCT aged 45-90 years old (median age of 73).22,23 Patients were randomized to receive either DARZALEX®-Rd or Rd alone in 28-day cycles.24 In the DARZALEX®-Rd treatment arm, patients received DARZALEX® 16 milligrams per kilogram (mg/kg) through intravenous (IV) infusion weekly for cycles 1 – 2, every two weeks for cycles 3 – 6 and every 4 weeks for cycle 7 and thereafter.25 Patients in both the DARZALEX®-Rd and Rd treatment arms received 25 mg of lenalidomide on days 1 – 21 of each 28-day cycle and dexamethasone at 40 mg once a week for each cycle. Patients in both treatment arms continued until disease progression or unacceptable toxicity.26
About DARZALEX® (daratumumab) DARZALEX® is the first CD38-directed monoclonal antibody (mAb) approved to treat multiple myeloma. It binds to CD38, a surface protein highly expressed across multiple myeloma cells.27 DARZALEX® induces tumor cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).28 DARZALEX® has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response. 29 Additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant hematologic diseases in which CD38 is expressed, such as smoldering myeloma.30,31
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX®. Janssen Inc. commercializes DARZALEX® in Canada. For full Prescribing Information and more information about DARZALEX®, please visit www.janssen.com/canada.
About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/canada. Follow us at @JanssenCanada. Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
*Dr. Bahlis was not compensated for any media work. He has been compensated as a consultant.
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DARZALEX®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
PSYCHOLOGIST CAN ANSWER QUESTIONS ON COPING WHEN THE CLOCKS “FALL BACK"
Expert Resource For Articles On Mental Wellness, Stress, Parenting, Relationships, Depression, Anxiety, Addiction, Adhd And More!!
The clocks “fall back” November 3, 2019, which means that there will be less daylight. Many people chalk up feeling blue in winter as simply a fact of cold weather and lack of sunshine. But 4 to 6 percent of people may have a winter depression which is clinically referred to as Seasonal Affective Disorder. Another 10 to 20 percent may have mild SAD. SAD is four times more common in women than in men. Although some children and teenagers get SAD, it usually doesn't start in people younger than age 20. Your chance of getting SAD goes down as you get older. SAD is also more common the farther north you go. For example, it's seven times more common in Washington State than in Florida. Dr. Sanam Hafeez is a neuro-Psychologist in NYC (Manhattan and Forest Hills, Queens), and treats patients in her practice who display and express mood changes once October rolls around.
Dr. Hafeez has been a trusted and recurring expert across media channels for top outlets such as: The Wallstreet Journal, The Washington Post, HuffPost, The New York Times, Bustle, Elite Daily, Refinery29, Prevention, Health, Healthline and on TV for such shows and news as Good Day New York, Dr. OZ, The Doctors, CNN, CBS NY Weekend News, and FOX. She is a neuropsychologist in NYC with a faculty appointment at Columbia University. She specializes in neuropsychological, educational and developmental evaluations with a focus on bilingual and culturally sensitive assessments, forensic evaluations (custody, competency, immigration), expert witness testimony, learning disabilities, autism, ADHD, traumatic brain injury, and psychopathology (bipolar, schizophrenia, depression, anxiety.)
Dr. Hafeez can tackle a large variety of topics as a Neuropsychologist Brain Expert and Therapist.
Topics she can contribute to include (but are not limited to):
Relationships: Trust, Bonding, Declines in affection, Love Loss, Break Ups, Navigating Difficult Conversations, Expressing our feelings, Learning to listen, etc.
Disorders, Conditions, and other important topics: Seasonal Affect Disorder, PTSD, Depression, Stress, Sleep deprivation, social anxiety, self-consciousness, self-confidence, empowerment and community, representation and self-perception, fears, and challenges.
Family Dynamics: Children, Developmental conditions, Divorce, Teens, Elderly Parents, Grief, Single Parenting, Behavioral issues.
Sleep: Sleep-hygiene, Night Owls/Early Birds, Productivity, Positive Mentalities, Brain Hacks.
Protect Yourself this Cold Season with New BETADINE® COLD DEFENCE™ Nasal Spray
New product is clinically proven to help treat colds when used at the first sign and help shorten the duration of a cold to help you feel better, faster!
PICKERING, ON, Oct. 29, 2019 /CNW/ -Having a congested nose and sore throat often go hand-in-hand with the arrival of cooler weather in Canada. In fact, adults can experience 4-6 colds each year and children can have even more1. Colds can leave you feeling run down and account for 40% of unplanned time off work and 30% of school absences in Canada1. This season take care of yourself and your family with BETADINE®COLD DEFENCE™ Nasal Spray, a new early infection treatment product clinically proven to help defend against colds and shorten the duration of a cold when used at the first sign.
The Importance of Early Infection Treatment
BETADINE®, the trusted leader in infection treatment and protection, has launched BETADINE® COLD DEFENCE™ Nasal Spray for the early treatment of viruses, the most common cause of colds2.
When used at the first sign of cold symptoms, BETADINE® is proven to help reduce the length of a cold and prevent viruses from spreading and multiplying. By trapping and disabling the cold virus and reducing the number of cold viruses in the nose, BETADINE® can help defend against colds, which is especially important for parents with young children and individuals with weakened immune systems who are more susceptible to illness.
"No one enjoys being sick – myself included – and while the goal is always to avoid getting sick in the first place, sometimes medicine is required," says Professor Ronald Eccles, former Director at the Common Cold Centre, Cardiff University and current Professor Emeritus in the School of Biosciences at Cardiff University. "Early infection treatment is a key innovation in cough and cold treatment. Addressing viruses at the earliest sign is essential for quick recovery and has the added benefit of preventing the spread of the cold, keeping all those around you healthy throughout cough and cold season."
Cold Treatment That Goes Beyond Symptom Management
When a cold strikes, managing symptoms is important, but a full and speedy recovery is always the goal. BETADINE® goes beyond addressing the symptoms of a cold by defending against the viruses that are the root cause of the discomfort, congestion, runny nose and upper respiratory tract infections that accompany the common cold. BETADINE® COLD DEFENCE™ Nasal Spray directly attacks the viruses that cause the common cold by trapping and disabling them in the nasal cavity. The disabled viruses are then expelled with the product the next time you blow your nose. The result: a reduced duration for the common cold – not just management of the worst symptoms.
"Many cough and cold products on the market focus on symptom management to get you through the one to two-week duration of the average cold," says Professor Eccles. "By blocking the viruses that cause the common cold, BETADINE® COLD DEFENCE™ Nasal Spray is able to reduce the length and severity of colds and manage cold symptoms."
About BETADINE®COLD DEFENCE™ Nasal Spray
BETADINE® COLD DEFENCE™ Nasal Spray is an over-the-counter treatment which is clinically proven to defend against colds and to shorten the duration of colds when used at the first sign. It works by helping to trap and disable cold viruses, preventing them from spreading and multiplying in the nasal cavity.
Clinically proven to defend against colds
Antibiotic-free
Soothes and hydrates nasal passages
Relieves congestion and runny nose
Safe for the whole family: BETADINE® COLD DEFENCE™ Nasal Spray is safe for use by adults and children ages 4 and up, and children 1 year old and up with the recommendation of a Health Care Practitioner.
BETADINE® COLD DEFENCE™ Nasal Spray and the family of BETADINE® Sore Throat products are available for purchase at major pharmacies and retailers across Canada. For more information, please visit www.betadine.ca.
About AVRIO Health™ Canada AVRIO Health™ is the Consumer Health division of Purdue Pharma (Canada). AVRIO Health™ champions an improved quality of life through innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including SENOKOT® and BETADINE®, and we leverage the best ideas from around the world to protect and promote health and well-being.
- 30 -
BETADINE® is a registered trademark of Purdue Pharma (Canada).
Homewood Ravensview Welcomes Chief Rebecca David of the Pauquachin First Nation to the Position of Cultural Liaison
Innovative new position coordinates cultural practices and support programs at the landmark mental health and addictions treatment centre on the Saanich Peninsula
VICTORIA, Oct. 29, 2019 /CNW/ - Homewood Ravensview is pleased to announce that it has hired Chief Rebecca David of the Pauquachin First Nation to serve as Ravensview's first Indigenous Cultural Liaison. Reporting directly to the centre's General Manager, Robert De Clark, David is responsible for cultivating strong relationships with Indigenous leaders, Elders, communities and agencies as she works to increase Homewood's organizational understanding of and engagement with First Nations perspectives. She will also help design and deliver programs that incorporate First Nations knowledge, practices and ceremonies.
"This is an important part of our mission here," said De Clark. "We worked closely with our First Nations partners to develop Ravensview and we will continue to respect and engage Indigenous cultures in our day-to-day work – everything from how we deliver care to how we design our client experience. It's a real privilege to have someone with Rebecca's unique credentials and experiences leading that effort."
David brings to her work at Ravensview exceptional qualifications in both community leadership and addictions and mental health support. She has been Chief of the Pauquachin First Nation since her election in October 2014 and serves on the board of directors of the British Columbia Assembly of First Nations and the board of trustees for the National Indian Brotherhood Trust. Earlier in her career she was a project co-leader and an employment counsellor with the Tillicum Lelum Aboriginal Friendship Centre, an instructor at Vancouver Island University and an alcohol and drug counsellor at Tsowtun Lelum. David earned a Diploma in Social Work at Malaspina College University, a Bachelor's degree in Child and Youth Care from Vancouver Island University, a Master's in Business Administration from Vancouver Island University and a Master's of International Business and Science from the University of Hertfordshire.
"I feel like so much of my education and experience has been leading to an opportunity like this," said David. "We are in a position at Ravensview to help hundreds of people every year. Enriching our program and enhancing our results by incorporating First Nations traditions and perspectives is going to create an important legacy here on the mountain we call ȽÁU,WELṈEW̱ … our 'place of refuge'."
As Indigenous Cultural Liaison, David's diverse portfolio will include establishing the overall vision and goals for the Indigenous cultural support program; providing clients with cultural support; developing cultural safety training and practices for staff; designing resources, workshops and events that incorporate Indigenous elements; and liaising with local First Nations to ensure support for Coast Salish protocols.
Anyone interested in learning more about Homewood Ravensview programs or self-admission to Ravensview should visit ravensview.com/contact or call 1.866.203.1793.
About Homewood Health Homewood Health is Canada's leader in the delivery of national mental health and addiction services. With more than 135 years of experience, Homewood achieves outstanding outcomes through its national network of more than 4,500 employees and clinical experts. Homewood's complete suite of services includes organizational wellness, employee and family assistance programs, assessments, outpatient and inpatient treatment, recovery management, return to work and family support services, all customized to meet the needs of individuals and organizations.
About Homewood Ravensview Homewood Ravensview, part of Homewood Health, offers treatment for mental health, addiction and concurrent conditions. The centre is located on 28 acres of forested hillside on Vancouver Island's Saanich Peninsula and focuses on creating individualized client experiences. Homewood Ravensview features forest and ocean views from private and semi-private bedrooms, suites and welcoming common areas. Homewood Ravensview opened in May 2019 with 75 beds and more than 80 full-time staff.
SOURCE Homewood Health Inc.
Simple Steps to Avoid Dangers of the Flu for Older Adults
Home Instead Senior Care urges families to take preventative measures to avoid illness, hospitalization
TORONTO, Oct. 29, 2019 /CNW/ - It's the time of year everyone dreads: flu season. Each year in Canada, more than 12,000 people are hospitalized due to the flu according to Public Health Canada. People over the age of 65 are at greater risk for these complications, in this age group it is estimated that 125 to 228 per 100,000 healthy persons make up flu-related hospitalizations, and mortality rates increase with age.
"In addition to fever and respiratory symptoms, older adults are at an increased risk for complications such as heart attack or stroke and hospitalization from the flu virus," said Lakelyn Hogan, gerontologist with Home Instead Senior Care. "Home Instead CAREGivers see firsthand how vulnerable older adults are to the flu virus and the critical role prevention plays in avoiding the dangers of flu season."
To help reduce the chance of loved ones contracting the flu and ending up in the hospital this winter, Home Instead recommends the following:
Make sure your loved one receives a flu vaccine. The best time to get a flu shot is before flu season is in full swing. The vaccine should not be limited to just older adults. Caregivers and family members should be vaccinated to stay healthy and protect older loved ones.
Take daily preventative measures. It might sound simple but washing your hands and avoiding those who are sick can go a long way. The Canadian Red Cross lists seven healthy habits to stop germs, including touching your eyes, nose or mouth and sanitizing properly.
Encourage physical activity. Moderate exercise boosts the immune system and could reduce the risk of a cold, according to Harvard Health. Even in frigid winter temperatures, activities such as a walk at a community recreation center or simple strength training exercises at home using household items and body weight can boost immunity.
Pay attention to the signs and symptoms. Frequently check in on loved ones. Pay close attention to symptoms and changes in appearance or demeanor. Encourage regular doctor visits to help keep minor symptoms from turning into more serious issues. It's important to know all symptoms of the flu and get treatment as soon as possible.
Take extra precautions to prevent hospitalizations. Simple steps, such as acknowledging symptoms of illness when they first appear, reducing risks of falls around the home and maintaining a healthy diet can all have a substantial impact on protecting older adults from hospitalization and further infection.
ABOUT HOME INSTEAD SENIOR CARE The Home Instead Senior Care network provides personalized care, support and education to help enhance the lives of aging adults and their families. Today, this network is the world's leading provider of in-home care services for seniors, with more than 1,100 independently owned and operated franchises that provide more than 70 million hours of care throughout Canada and 11 other countries. Local Home Instead Senior Care offices employ approximately 70,000 CAREGiversSM worldwide who provide basic support services that enable seniors to live safely and comfortably in their own homes for as long as possible. The Home Instead Senior Care network works with clients and their family members to meet varied individual needs. Services span the care continuum – from providing personal care to specialized Alzheimer's care and hospice support. Also available are family caregiver education and support resources.
SOURCE Home Instead Senior Care
Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./
TORONTO, Oct. 29, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announces that its executive officers and directors have entered into voluntary lock-up agreements to extend the term of their lock-up periods, affecting approximately 7.7 million shares. The Company also announces that Kyle Langstaff has stepped down as Vice President (Operations) and has concurrently entered into a lock-up agreement to restrict the disposition of his common shares. In addition, the Company's board of directors has separated the roles of Chairman and Chief Executive Officer.
Extended Lock-Up Agreements
Each member of the Company's board of directors has entered into voluntary lock-up agreements pursuant to which they will not sell, transfer or pledge any of their Avicanna securities prior to July 1, 2020. On July 1, 2020, the Company will release 10% of such securities to the respective directors, with the remaining securities released in six equal tranches of 15% every six months following the first release, subject to customary exceptions. The members of the board of directors hold an aggregate of 7,176,850 common shares of the Company.
The executive officers of the Company have entered into voluntary lock-up agreements pursuant to which they will not sell, transfer or pledge any of their Avicanna securities prior to January 1, 2020. On January 1, 2020, the Company will release 10% of such securities to the respective executives, with the remaining securities released in six equal tranches of 15% every six months following the first release, subject to customary exceptions. The executive officers hold an aggregate of 540,743 common shares of the Company.
In addition, each director and officer entering into one of the voluntary lock-up agreements described above will not sell more than 5,000 common shares of the Company in any one week period during the first year following the initial release date under such agreement, without the consent of the Company.
Upon release of the securities subject to the extended lock-up agreements, the executive officers and directors will remain subject to all applicable black-out periods under the Company's insider trading policy, which is available on Avicanna's website.
Additionally, Kyle Langstaff, non-management founder of Avicanna, has resigned as Vice President (Operations) for personal reasons, effective immediately. Mr. Langstaff holds an aggregate of 2,418,333 shares of the Company's common stock. As a demonstration of his confidence in the Company, Mr. Langstaff has entered into a voluntary lock-up agreement, pursuant to which he will not sell more than 10,000 common shares of the Company in any one week period prior to April 18, 2020, without the consent of the Company. Under Mr. Langstaff's lock-up agreement, 10% of his securities were released on October 18, 2019, and the remaining securities are to be released in six equal tranches of 15% every six months following the first release, subject to customary exceptions. As of the date hereof, Mr. Langstaff has not disposed of any of his securities of the Company.
Aras Azadian, the Company's Chief Executive Officer, stated, "These extended lock-up agreements demonstrate the confidence that the management team and the board of directors have in the Company's long-term potential. We believe these agreements will further strengthen the commitment of all stakeholders to achieving our goal of becoming an industry leader in organic and sustainable plant-derived cannabinoid-based products."
Separation of Chairman and CEO Roles
The Company's board of directors also decided to separate the roles of Chairman and Chief Executive Officer. Mr. Azadian will continue as the Company's Chief Executive Officer. Avicanna's board of directors appointed Dr. Chandrakant Panchal, current independent Lead Director, as the Company's Non-Executive Chairman, effective immediately.
Mr. Azadian, stated, "Avicanna's commitment to best practices extends to all areas of the Company. The separation of the Chairman and CEO roles is an important feature in an independent board and its duties to oversee the Company's operations. We are happy to appoint Dr. Panchal, who is an experienced director and biotechnology industry veteran, as Avicanna's Non-Executive Chairman."
"I am delighted and honored to be elected as non-executive Chairman of Avicanna. It is imperative that corporate governance is a priority for the Company. The separation of the roles of Chairman and CEO reflect the board and the Company's commitment to good corporate governance," said Dr. Chandrakant Panchal, the Company's Non-Executive Chairman.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the timing of securities releases, the maximum number of shares that will be sold by persons subject to the lock-up agreements in any one week period and the additional restrictions the securities will be subject to upon release from the lock-up agreements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
